XFRA:3LW Quarterly Report 10-Q/A Filing - 6/30/2012

Effective Date 6/30/2012

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10−Q/A

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2012

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to _____________ 

 

Commission File Number: 001-34484

 

WINNER MEDICAL GROUP INC.

(Exact name of Registrant as Specified in its Charter)

 

Nevada   33-0215298
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification. No.)

 

Winner Industrial Park, Bulong Road
Longhua, Shenzhen City, 518109
The People’s Republic of China
(Address of principal executive offices) (Zip Code)

 

  86-(755) 28138888  
  (Registrant’s telephone number, including area code)  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months or for such shorter period that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past 90 days.      Yes  x      No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).          Yes  x     No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ¨ No  x

 

The number of shares outstanding of the issuer’s class of common equity as of August 14, 2012 was 24,371,872.

 

 
 

 

TABLE OF CONTENTS

 

      Page
Explanatory Note   3
       
  PART I   5
       
Item 1. Financial Statements.   5
       
  PART II   6
       
Item 1. Legal Proceedings.   6
Item 6. Exhibits.   6

 

2
 

 

Explanatory Note

 

On August 9, 2012 (the “Original Filing Date”), Winner Medical Group Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the three months ended June 30, 2012 (the “Initial Form 10-Q”). This Quarterly Report on Form 10-Q/A (the “Form 10-Q/A”) amends Part I – Item 1, “Financial Statements,” Part II – Item 1, “Legal Proceedings,” and Part II – Item 6, “Exhibits,” specifically to include an update on the Company’s class action litigation in Nevada (the “Nevada Litigation Update”) to reflect developments that occurred on the Original Filing Date prior to the Company’s filing of the Initial Form 10-Q. As such, no other changes have been made herein to the Initial Form 10-Q.

 

The filing of this Form 10-Q/A shall not be deemed as an admission that the original filing, when made, included any untrue statement of material fact or omitted to state a material fact necessary to make a statement not misleading. Except as discussed above, the Company has not modified or updated disclosures presented in the Initial Form 10-Q. Accordingly, this amended quarterly report does not reflect events occurring after the Initial Form 10-Q or modify or update those disclosures affected by subsequent events, except as specifically referenced herein, and should be read in conjunction with the Company’s filings with the SEC subsequent to the filing of the Initial Form 10-Q. Information not affected by the Nevada Litigation Update is unchanged and reflects the disclosures made at the time of the Initial Form 10-Q. References to this “quarterly report on Form 10-Q,” this “quarterly report on Form 10-Q/A” and this “amended quarterly report on Form 10-Q/A” herein shall refer to the Initial Form 10-Q as amended by this amended quarterly report on Form 10-Q/A. The following items have been amended as a result of the Nevada Litigation Update:

 

·Part I – Item 1. Financial Statements;

 

·Part II – Item 1. Legal Proceedings; and

 

·Part II – Item 6. Exhibits.

 

3
 

 

Cautionary Statement

 

This Quarterly Report on Form 10-Q/A contains forward-looking statements that are based on the beliefs of the Company’s management and involve risks and uncertainties, as well as assumptions that, if they ever materialize or prove incorrect, could cause the results of the Company to differ materially from those expressed or implied by such forward-looking statements. The words “believes,” “expects,” “anticipates,” “projects,” “targets,” “optimistic,” “intends,” “aims,” “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding new and existing products, technologies and opportunities; statements regarding market and industry segment growth and demand and acceptance of new and existing products; any projections of sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in China; any statements of belief or intention; any of the factors mentioned in the “Risk Factors” section of the Company’s Annual Report on Form 10-K; and any statements of assumptions underlying any of the foregoing.

 

Except as otherwise indicated by the context, references in this report to “the Company,” “Winner,” “Winner Medical,” “we,” “us” or “our” are references to the combined business of Winner Medical Group Inc. and its subsidiaries. The English translation of the names of the Company’s subsidiaries which were incorporated in the People’s Republic of China (the “PRC”) is for reference only. The official names of the PRC subsidiaries are in Chinese.

 

4
 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1.           FINANCIAL STATEMENTS.

 

WINNER MEDICAL GROUP INC.

   

  Condensed Consolidated Financial Statements (Unaudited)

  For the three and nine months ended June 30, 2012 and 2011

 

5
 

 

WINNER MEDICAL GROUP INC.

 

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

  Page
   
Condensed Consolidated Balance Sheets F-1
   
Condensed Consolidated Statements of Income and Comprehensive Income F-2
   
Condensed Consolidated Statements of Stockholders’ Equity F-3
   
Condensed Consolidated Statements of Cash Flows F-4
   
Notes to Condensed Consolidated Financial Statements F-5 - F-20

 

 
 

 

WINNER MEDICAL GROUP INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   June 30,   September 30, 
   2012   2011 
   US$   US$ 
ASSETS          
Current assets:          
Cash and cash equivalents   25,225,650    21,945,105 
Restricted bank deposits   107,679    1,836,491 
Restricted broker margin account   475,106    0 
Accounts and notes receivable, less allowances for doubtful accounts of US$92,213 and US$159,485 at June 30, 2012 and September 30, 2011, respectively   23,789,096    20,982,263 
Amounts due from affiliated companies   84,550    157,779 
Inventories   25,500,169    25,408,700 
Prepaid expenses and other current assets   11,805,719    8,334,504 
Income taxes recoverable   234,400    146,408 
Deferred tax assets   345,293    376,411 
Total current assets   87,567,662    79,187,661 
Property, plant and equipment, net   69,678,053    65,461,750 
Investment in equity investees   2,573,325    2,421,915 
Intangible assets, net   148,340    126,918 
Prepaid expenses and other receivables   2,463,983    1,596,354 
Deferred tax assets   1,190,522    1,124,089 
Total assets   163,621,885    149,918,687 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Short-term bank loans   6,324,211    6,294,356 
Accounts payable   10,137,984    7,420,580 
Accrued payroll and employee benefits   3,508,256    3,141,756 
Customer deposits   1,099,714    1,115,887 
Accrued and other liabilities   6,822,643    4,253,889 
Amounts due to affiliated companies   85,402    0 
Income taxes payable   1,437,598    1,970,710 
Total current liabilities   29,415,808    24,197,178 
Deferred tax liabilities   0    45,025 
Total liabilities   29,415,808    24,242,203 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Common stock, par value $0.001 per share; authorized 247,500,000, issued and outstanding June 30, 2012 -24,371,872 shares; September 30, 2011 -24,140,247 shares   24,373    24,141 
Additional paid-in capital   43,559,598    42,490,464 
Retained earnings   65,635,028    58,984,686 
Statutory reserves   5,932,049    5,866,970 
Accumulated other comprehensive income   18,790,415    18,169,505 
Total Winner Medical Group Inc. stockholders’ equity   133,941,463    125,535,766 
           
Noncontrolling interests   264,614    140,718 
Total stockholder’s equity   134,206,077    125,676,484 
           
Total liabilities and stockholder’s equity   163,621,885    149,918,687 

 

See accompanying notes to condensed consolidated financial statements.

 

F-1
 

 

WINNER MEDICAL GROUP INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

(UNAUDITED) 

 

   Three months ended
 June 30,
   Nine months ended
 June 30,
 
   2012   2011   2012   2011 
   US$   US$   US$   US$ 
                 
Net sales   48,191,971    41,536,465    130,827,383    108,460,785 
                     
Cost of sales   (35,960,360)   (30,227,856)   (97,591,364)   (78,318,957)
Gross profit   12,231,611    11,308,609    33,236,019    30,141,828 
                     
Other operating income/(loss), net   144,329    (2,831)   218,960    (104,786)
Government subsidies   169,784    90,407    416,274    1,304,622 
Realized gain/(loss) on commodity financial instruments   92,791    65,037    167,467    (1,694,632)
Foreign currency exchange gain/(loss)   199,642    (270,910)   (83,240)   (415,041)
Selling, general and administrative expenses   (10,576,805)   (7,293,780)   (25,538,616)   (19,151,578)
                     
Income from operations   2,261,352    3,896,532    8,416,864    10,080,413 
Interest income   109,120    59,088    279,760    105,256 
Interest expense   (125,150)   (134,793)   (228,701)   (227,978)
Equity in earnings of 50 percent or less owned persons   69,945    179,745    151,410    362,860 
Income before income taxes   2,315,267    4,000,572    8,619,333    10,320,551 
                     
Income taxes   55,227    (565,349)   (1,840,529)   (1,287,744)
Net income   2,370,494    3,435,223    6,778,804    9,032,807 
                     
Net income attributable to noncontrolling interests   (43,210)   (10,698)   (63,383)   (44,102)
Net income attributable to Winner Medical Group Inc.   2,327,284    3,424,525    6,715,421    8,988,705 
                     
Comprehensive income:                    
Net income   2,370,494    3,435,223    6,778,804    9,032,807 
Foreign currency translation difference   (600,851)   1,385,899    621,397    3,757,299 
Comprehensive income attributable to noncontrolling interests   (41,732)   (10,672)   (63,870)   (44,452)
                     
Comprehensive income attributable to Winner Medical Group Inc.   1,727,911    4,810,450    7,336,331    12,745,654 
                     
                     
Net income attributable to Winner Medical Group Inc.  per share                    
- basic   0.10    0.14    0.28    0.37 
- diluted   0.09    0.14    0.27    0.37 
                     
Weighted average common stock outstanding                    
- basic   24,371,872    24,130,247    24,365,867    24,125,593 
- diluted   25,013,418    24,601,088    24,770,079    24,621,897 

 

See accompanying notes to condensed consolidated financial statements.

 

F-2
 

 

WINNER MEDICAL GROUP INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(UNAUDITED)

 

                       Accumulated         
   Common stock   Additional           other   Non-   Total 
   Stock       paid-in   Retained   Statutory   comprehensive   controlling   Stockholders’ 
   outstanding   Amount   capital   earnings   reserves   Income   interests   equity 
       US$   US$   US$   US$   US$   US$   US$ 
                                 
Balance at September 30, 2010   23,950,740    23,951    40,154,494    48,730,034    4,585,731    12,302,762    100,199    105,897,171 
                                         
Restricted stock units granted   0    0    618,129    0    0    0    0    618,129 
Stockholder’s contribution   0    0    1,718,031    0    0    0    0    1,718,031 
Issuance of restricted stock units   189,507    190    (190)   0    0    0    0    0 
                                         
Net income   0    0    0    11,535,891    0    0    39,772    11,575,663 
                                         
Foreign currency translation adjustments   0    0    0    0    0    5,866,743    747    5,867,490 
Transfer to statutory reserves   0    0    0    (1,281,239)   1,281,239    0    0    0 
Balance at September 30, 2011   24,140,247    24,141    42,490,464    58,984,686    5,866,970    18,169,505    140,718    125,676,484 
Restricted stock units and stock options granted   0    0    1,129,392    0    0    0    0    1,129,392 
Issuance of restricted stock units   231,625    232    (232)   0    0    0    0    0 
                                         
Net income   0    0    0    6,715,421    0    0    63,383    6,778,804 
                                         
Transfer from Statutory reserves   0    0    0    (65,079)   65,079    0    0    0 
Foreign currency translation adjustments   0    0    0    0    0    620,910    487    621,397 
Contribution from noncontrolling interests   0    0    0    0    0    0    474,593    474,593 
Purchase of noncontrolling interests   0    0    (60,026)   0    0    0    (414,567)   (474,593)
                                         
Balance at June 30, 2012   24,371,872    24,373    43,559,598    65,635,028    5,932,049    18,790,415    264,614    134,206,077 

 

See accompanying notes to condensed consolidated financial statements.

 

F-3
 

 

WINNER MEDICAL GROUP INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   Nine months ended
 June 30,
 
   2012   2011 
   US$   US$ 
Cash flows from operating activities          
Net income   6,778,804    9,032,807 
Adjustments to reconcile net income to net cash from operating activities:          
Depreciation and amortization of property, plant and equipment   4,594,318    4,030,486 
Amortization of intangible assets   26,267    20,789 
Loss on disposal of property, plant and equipment   129,211    246,097 
Impairment of property, plant and equipment   1,464,403    0 
Change in fair value of financial instruments, net   (3,028)   (71,071)
Equity in earnings of 50 percent or less owned persons   (151,410)   (362,860)
Investment income from held-to-maturity investments   (197,441)   (55,835)
Stock-based compensation expenses   1,129,392    644,726 
Gain on realized commodity financial instruments   (74,496)   0 
Deferred tax   (73,436)   (589,145)
Changes in operating assets and liabilities:          
Restricted bank deposits   1,575,114    193,677 
Restricted broker margin account   (400,610)   (1,293,173)
Accounts receivable   (2,707,311)   (4,254,544)
Amounts due from affiliated companies   73,977    (7,208)
Inventories   29,048    (8,676,339)
Prepaid expenses and current assets   (3,438,644)   (3,949,729)
Income taxes recoverable   (87,298)   7,061 
Accounts payable   2,682,207    2,582,464 
Accrued payroll and employee benefits   351,598    458,738 
Customer deposits   (21,467)   11,332 
Accrued and other liabilities   1,978,259    309,727 
Amounts due to affiliated companies   85,402    653 
Income taxes payable   (537,882)   84,838 
Net cash provided by/ (used in)  operating activities   13,204,977    (1,636,509)
           
Cash flows from investing activities          
Purchase of property, plant and equipment   (7,733,003)   (5,070,594)
Purchase of intangible assets   (47,031)   (23,904)
Proceeds from disposal of property, plant and equipment   40,585    39,139 
Deposits paid for property, plant and equipment   (2,244,371)   (1,589,928)
Redemption of held-to-maturity investments   36,480,515    31,229,055 
Purchase of held-to-maturity investments   (36,283,074)   (29,647,424)
Net cash used in investing activities   (9,786,379)   (5,063,656)
           
Cash flows from financing activities          
Proceeds from bank borrowings   9,461,036    12,752,313 
Repayment of bank borrowings   (9,461,036)   (4,390,219)
Purchase of noncontrolling interests   (425,747)   (211,490)
Restricted bank deposits   157,756    0 
Net cash (used in)/provided by financing activities   (267,991)   8,150,604 
           
Effect of exchange rate changes   129,938    723,033 
           
Net increase in cash and cash equivalents   3,280,545    2,173,472 
Cash and cash equivalents, beginning of period   21,945,105    14,818,179 
Cash and cash equivalents, end of period   25,225,650    16,991,651 
           
Supplemental disclosures of cash flows information:          
Cash paid during the period for:          
Cash paid for interest, net of capitalized interest of US$183,875 and US$Nil during the nine months ended June 30, 2012 and 2011, respectively   228,701    227,978 
Income taxes   2,542,999    1,864,125 

 

See accompanying notes to condensed consolidated financial statements.

 

F-4
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1.  Basis of Preparation of Financial Statements

 

The accompanying condensed consolidated financial statements of Winner Medical Group Inc (“Winner Medical” or the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim consolidated financial information. Accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements.

 

In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair presentation of the operating results for the three and nine months ended June 30, 2012 have been made. It is suggested that these condensed consolidated financial statements be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended September 30, 2011. The Company follows the same accounting policies in preparation of interim reports.

 

Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

 

2.  Description of Business

 

The principal activities of the Company and its subsidiaries consist of research and development, manufacturing and trading of medical dressings, medical disposables and PurCotton® products. Activities of the Company are principally conducted by subsidiaries operating in the People’s Republic of China (the “PRC”).

 

3.  Recently Issued Accounting Pronouncements

 

In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement (ASC 820) Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. This pronouncement is an authoritative guidance to amend certain measurement and disclosure requirements related to fair value measurements to improve consistency with international reporting standards. In addition, ASU 2011-04 expanded the required disclosures around fair value measurements including (i) reporting the level in the fair value hierarchy used to value assets and liabilities which are not measured at fair value, but where fair value is disclosed, and (ii) qualitative disclosures about the sensitivity of Level 3 fair value measurements to changes in unobservable inputs used. This guidance is effective prospectively for public entities for interim and annual reporting periods beginning after December 15, 2011, with early adoption by public entities prohibited, and is applicable to the Company’s fiscal year beginning October 1, 2012. The Company is currently evaluating this guidance, but does not expect its adoption will have a material effect on its consolidated financial statements.

 

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (ASC 220) Presentation of Comprehensive Income (“ASU No. 2011-05”). This pronouncement is an authoritative guidance on the presentation of comprehensive income that will require a company to present components of net income and other comprehensive income in one continuous statement or in two separate, but consecutive statements. There are no changes to the components that are recognized in net income or other comprehensive income under current GAAP. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011, with early adoption permitted. The Company has adopted ASU No. 2011-05 for its 2012 fiscal year.

 

In December 2011, the FASB issued ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”) to ASC 210, Balance Sheet. The update requires new disclosures about balance sheet offsetting and related arrangements. For derivatives and financial assets and liabilities, the amendments require disclosure of gross asset and liability amounts, amounts offset on the balance sheet, and amounts subject to the offsetting requirements but not offset on the balance sheet. The guidance is effective December 1, 2013 and is to be applied retrospectively. This guidance does not amend the existing guidance on when it is appropriate to offset. The Company is currently evaluating this guidance, but does not expect its adoption will have a material effect on its consolidated financial statements.

 

F-5
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

4.  Net Income Attributable to Winner Medical Group Inc. Per Share

 

Net income attributable to Winner Medical Group Inc. per share- Basic net income attributable to Winner Medical Group Inc. per share is computed by dividing net income attributable to Winner Medical Group Inc. available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net income attributable to Winner Medical Group Inc. per share gives effect to all dilutive potential ordinary shares outstanding during the period. The weighted average number of common shares outstanding is adjusted to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. For the three and nine months ended June 30, 2012 and 2011, the basic and diluted net income attributable to Winner Medical Group Inc. per share calculated in accordance with ASC 260, "Earnings Per Share", are reconciled as follows:

 

   Three months ended
 June 30,
 
   2012   2011 
   US$   US$ 
Basic income per share          
           
Net income attributable to Winner Medical Group Inc. for the period   2,327,284    3,424,525 
           
Weighted average common stock outstanding   24,371,872    24,130,247 
           
Net income attributable to Winner Medical Group Inc. per share   0.10    0.14 
           
Diluted income per share          
           
Net income attributable to Winner Medical Group Inc. for the period   2,327,284    3,424,525 
           
Weighted average common stock outstanding   24,371,872    24,130,247 
           
Effect of dilution          
           
Restricted stock   412,235    470,841 
Options   229,311    0 
           
Weighted average common stock outstanding   25,013,418    24,601,088 
           
Net income attributable to Winner Medical Group Inc. per share   0.09    0.14 

 

   Nine months ended
 June 30,
 
   2012   2011 
   US$   US$ 
Basic income per share          
           
Net income attributable to Winner Medical Group Inc. for the period   6,715,421    8,988,705 
           
Weighted average common stock outstanding   24,365,867    24,125,593 
           
Net income attributable to Winner Medical Group Inc. per share   0.28    0.37 
           
Diluted income per share          
           
Net income attributable to Winner Medical Group Inc. for the period   6,715,421    8,988,705 
           
Weighted average common stock outstanding   24,365,867    24,125,593 
           
Effect of dilution          
           
Restricted stock   343,397    496,304 
Options   60,815    0 
           
Weighted average common stock outstanding   24,770,079    24,621,897 
           
Net income attributable to Winner Medical Group Inc. per share   0.27    0.37 

 

The number of stock options excluded from the calculation of diluted earnings per share for each of the three months ended June 30, 2012 and 2011, was nil; the number of stock options excluded from the calculation of diluted earnings per share for the nine months ended June 30, 2012 and 2011, was 350,000 and nil, respectively, because their inclusion would have been anti-dilutive. As of June 30, 2011, there were no potential dilutive common shares relating to stock options in the Company.

 

F-6
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

5.  Held-to-maturity investments

 

As of June 30, 2012 and September 30, 2011, there were no held-to-maturity investments. The Company had held-to-maturity investments during the three and nine months ended June 30, 2012 and 2011, which were money management products. Interest on these investments of US$81,455 and US$37,221 was included in interest income during the three months ended June 30, 2012 and 2011, respectively; US$197,441 and US$55,835 during the nine months ended June 30, 2012 and 2011, respectively.

 

6.  Inventories

 

Inventories by major categories are summarized as follows:

 

   June 30,   September 30, 
   2012   2011 
   US$   US$ 
Raw materials   10,872,422    10,851,917 
Work-in-progress   6,341,270    7,086,688 
Finished goods   8,286,477    7,470,095 
    25,500,169    25,408,700 

 

7.  Credit Facilities and Pledged Assets

 

The Company’s subsidiaries in Shenzhen and Huanggang have credit lines with Shenzhen Commercial Bank, Shenzhen Branch of the Industrial and Commercial Bank of China and Huanggang Branch of the Agricultural Development Bank of China, representing trade acceptances, loans and overdrafts.

 

As of June 30, 2012, the Company had approximately US$30.04 million bank credit facilities from three commercial banks and, after utilizing bank loans of US$6.32 million, there are $23.72 million available under bank credit facilities, consisting of approximately US$6.32 million from Shenzhen Branch of China Merchants Bank, approximately $12.65 million from Shenzhen Branch of the Industrial and Commercial Bank of China and approximately US$4.75 million from Huanggang Branch of Agricultural Development Bank of China. These facilities mature in August 2012 and October 2014. The weighted average interest rates on short-term borrowings as of June 30, 2012 and September 30, 2011, were 7.46% and 6.98% per annum, respectively. There are no significant covenants or other financial restrictions relating to the Company’s facilities except that, at June 30, 2012, buildings with net book values of US$3,752,034, plant and machinery with net book values of US$11,891,465 and, at September 30, 2011, buildings with a net book value of US$3,857,373 have been pledged as collateral for the above-mentioned facilities.

 

As of June 30, 2012 and September 30, 2011, the Company had the following short-term bank loans:

 

   June 30,   September 30, 
   2012   2011 
   US$   US$ 
         
Bank loans repayable within one year   6,324,211    6,294,356 
           
Original currency in Chinese Renminbi   40,000,000    40,000,000 

 

Bank loans as of June 30, 2012 that are secured by buildings and plant and machinery consisted of the following:

 

        June 30, 
        2012 
Loan   Loan period   US$ 
 A    November 28, 2011 to September 16, 2012    3,162,105 
 B    December 29, 2011 to September 16, 2012    3,162,106 
           6,324,211 

 

F-7
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED) 

 

8.  Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consist of the following:

 

   June 30,   September 30, 
   2012   2011 
   US$   US$ 
         
Value added tax receivable   6,198,898    4,717,557 
Advance to suppliers   3,390,705    1,626,030 
Rental deposit   864,628    684,424 
Other deposit   538,131    826,325 
Deferred expenditure   317,617    130,666 
Fair value of financial instruments   0    51,141 
Others   495,740    298,361 
    11,805,719    8,334,504 

 

9.  Income Taxes

 

United States

 

The Company is incorporated in Nevada in the United States of America and is subject to U.S. federal taxation. No provisions for income taxes have been made as the Company has no taxable income for the first quarter. The applicable income tax rate for the Company for each of the three and nine months ended June 30, 2012 and 2011, was 34%.

 

Cayman Islands

 

Winner Group Limited, a wholly owned subsidiary of the Company, is incorporated in the Cayman Islands and, under the current laws of the Cayman Islands, is not subject to income taxes.

 

Hong Kong

 

Winner Medical (Hong Kong) Limited (“Winner HK”), a 60% owned subsidiary of the Company, is incorporated in Hong Kong. Winner HK is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. Winner HK was incorporated in January 2008 and the applicable statutory tax rate for the subsidiary for the three and nine months ended June 30, 2012 and 2011, was 16.5%.

 

On January 25, 2011, a wholly-owned subsidiary HK PurCotton Co., Ltd., or “HK PurCotton” was established. The applicable income tax rate for HK PurCotton was 16.5% for the three and nine months ended June 30, 2012 and 2011.

 

PRC

 

Effective on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose an unified enterprise income tax rate of 25% on all domestic-invested enterprises and foreign investment enterprises in the PRC, unless they qualify under certain limited exceptions.

 

The EIT Law gives existing foreign investment enterprises a five-year grandfather period, during which they can continue to enjoy their existing preferential tax treatments. For foreign investment enterprises that currently enjoy full exemption from PRC enterprise income tax for two years starting from the first profit-making year, followed by a 50% tax exemption for the next three years, the tax holidays are still valid.

 

Winner Medical (Huanggang) Co., Ltd. enjoyed its full tax exemption from January 1, 2008 and its 50% tax exemption from January 1, 2010 to December 31, 2012. Winner Medical & Textile Ltd., Chongyang enjoyed its 50% tax exemption from January 1, 2008 and was subject to an enterprise income tax rate of 25% from January 1, 2011. Shanghai Winner Medical Apparatus Co., Ltd. enjoyed its 50% tax exemption from January 1, 2009 and would be subject to an enterprise income tax of 25% from January 1, 2012. Hubei Winner Textiles Co., Ltd. was subject to an enterprise income tax rate of 25% from January 1, 2010.

 

F-8
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

9.  Income Taxes - Continued

 

On September 11, 2009, Winner Industries (Shenzhen) Co., Ltd., or "Winner Shenzhen", obtained a High and New Technology Enterprise Certificate from the Ministry of Science and Technology of China, the Ministry of Finance and the State Administration of Taxation. Winner Shenzhen enjoyed an applicable preferential income tax rate of 15% from January 1, 2009 to December 31, 2011. According to the State Administration of Taxation Notice [2011] No. 4, High and New Technology enterprises applying for renewal of their status can file and pay taxes at a 15% rate prior to receiving approval of renewal and within the previously approved qualifying period. Management expects that Winner Shenzhen will be certified as a High and New Technology enterprise during the calendar year ending December 31, 2012. Accordingly, the applicable enterprise income tax rate for Winner Shenzhen is 15% for the period from January 1 to June 30, 2012.

 

The Company classifies all interest and penalties related to unrecognized tax benefits, if any, as a component of income tax provisions. The Company performed a self-assessment and the Company’s liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by tax authorities. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. At June 30, 2012, the management considered that the Company had no uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for uncertain positions in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three and nine months ended June 30, 2012 and 2011, respectively. The Company’s uncertain tax positions related to open tax years are subject to examination by the relevant tax authorities, the major one being the China Tax Authority. The open period for examination in the PRC is 5 tax years.

 

A reconciliation between the provision for income taxes computed by applying the statutory tax rate in PRC to income before income taxes and the actual provision for income taxes is as follows:

 

   Nine months ended
 June 30,
 
   2012   2011 
   US$   US$ 
         
Tax calculated at domestic statutory rate (2012: 25%; 2011: 25%)   2,154,833    2,580,138 
Effect of different tax rates in various jurisdictions   293,335    96,791 
Tax effect of preferential tax treatment   (1,165,904)   (1,161,515)
Tax effect of preferential tax treatment on research and development expenses   (321,570)   0 
Tax effect of expenses not deductible for tax purpose   18,311    32,195 
Tax effect of government subsidies not subject to tax   0    (189,764)
Change in valuation allowance   907,223    (44,260)
Under/(over) provision in previous years   48,857    (70,523)
Utilization of tax loss   (77,169)   0 
Others   (17,387)   44,682 
    1,840,529    1,287,744 

 

10. Related Party Transactions

 

During the three months ended June 30, 2012 and 2011, the Company purchased goods from L+L Healthcare Hubei Co., Ltd. (“L+L”), an equity investee, for US$24,679 and US$6,861, respectively, and sold goods to it for US$315,019 and US$18,373, respectively. During the nine months ended June 30, 2012 and 2011, the Company purchased goods from L+L for US$56,408 and US$139,817, respectively, and sold goods to it for US$$824,169 and US$40,466, respectively. As of June 30, 2012 and September 30, 2011, the amounts due from L+L were US$79,525 and US$119,368, respectively. L+L Healthcare Hubei Co., Ltd declared dividends of US$Nil to the Company for each of the three months ended June 30, 2012 and 2011; US$Nil and US$200,000 to the Company for the nine months ended June 30, 2012 and 2011, respectively.

 

During the three months ended June 30, 2012 and 2011, the Company sold goods to Chengdu Winner Likang Medical Appliance Co., Ltd. (“Winner Chengdu”), an equity investee, for US$13,596 and US$7,613, respectively, and purchased goods from it for US$66,759 and US$22,305, respectively. During the nine months ended June 30, 2012 and 2011, the Company sold goods to Winner Chengdu, for US$58,564 and US$11,458, respectively, and purchased goods from it for US$237,265 and US$63,433, respectively. As of June 30, 2012 and September 30, 2011, amounts due to Winner Chengdu were US$85,402 and US$Nil, respectively. As of June 30, 2012 and September 30, 2011, amounts due from Winner Chengdu were US$5,025 and US$38,411, respectively.

 

The amounts due from/to the above affiliated companies are unsecured, interest free and payable according to the trading credit terms.

 

F-9
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

10. Related Party Transactions - Continued

 

On January 1, 2011, Mr. Jianquan Li, the chief executive officer of the Company, entered into agreements with the Company in relation to commodity derivatives trading activities. In the agreements, as of September 30, 2011, the shortfall between the restricted broker margin account balance maintained for the commodity derivatives trading activities and the balance in that account on January 1, 2011, or US$2,838,000, was to be undertaken by Mr. Jianquan Li by way of cash payment from Mr. Jianquan Li to the Company on September 30, 2011. The Company accounts for this transaction between the Company and Mr. Jianquan Li in accordance with Staff Accounting Bulletin Topic 5T, under which the payment from Mr. Jianquan Li for the shortfall was recognized in additional paid-in capital as of September 30, 2011. The loss from trading in commodity financial instruments for the nine months ended June 30, 2011 of US$1,694,632 has been recognized in the consolidated statements of income and comprehensive income.

 

11. Stock-Based Compensation

 

Stock-Based Compensation - The Company has adopted ASC 718, ''Compensation-Stock Compensation'', which requires that share-based payment transactions with employees, such as share options, be measured based on the grant-date fair value of the equity instrument issued and recognized as compensation expense over the requisite service period, with a corresponding addition to equity. Under this method, compensation cost related to employee share options or similar equity instruments is measured at the grant date based on the fair value of the award and is recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period. Compensation expense is recognized for those awards that are expected to vest, which the Company’s estimates based upon historical forfeitures.

 

There was no stock-based compensation cost recorded for independent directors for the three and nine months ended June 30, 2012 and 2011, respectively.

 

On October 7, 2007, the Board of Directors approved a 2008-09 Restricted Stock Unit Incentive Plan, the “2008-2009 Plan”, a stock incentive compensation program for fiscal years 2008 and 2009. This 2008-2009 Plan allows the Company to offer a variety of restricted stock unit awards to directors, senior management and key employees, where a participant will be eligible to receive one share of the Company’s common stock for each restricted stock unit that vests upon the achievement of corporate and individual objectives and such participant’s continued employment as of the applicable vesting date.

 

Under the 2008-2009 Plan, the Company granted 500,000 units out of the total 600,000 authorized restricted stock units on October 7, 2007. Entitled employees are eligible to vest the first 50% of the total number of restricted stock awarded on October 7, 2010 and the second 50% on October 7, 2011 if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of the grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of October 7, 2007, which was US$3.60 per share, and assumes that the individual achieves the applicable corporate and individual objectives set forth in the award.

 

On October 15, 2008, the Board of Directors approved the granting of the remaining 100,000 units out of the total 600,000 authorized restricted stock units under the 2008-2009 Plan. Entitled employees are eligible to vest the first 50% of the total number of restricted stock awarded on October 7, 2010 and the second 50% on October 7, 2011 if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of October 15, 2008, which was US$0.50 per share, and assumes that the individual achieves of the applicable corporate and individual objectives set forth in the award.

 

On September 8, 2009, the Board of Directors approved the 2010-11 Restricted Stock Unit Incentive Plan, the “2010-2011 Plan”, a stock incentive compensation program for fiscal years 2010 and 2011. The 2010-2011 Plan allows the Company to offer a variety of restricted stock unit awards to directors, senior management and key employees, where a participant will be eligible to receive one share of the Company’s common stock for each restricted stock unit that vests upon the achievement of corporate and individual objectives and such participant’s continued employment as of the applicable vesting date.

 

Under the 2010-2011 Plan, the Company granted 250,000 units out of the total 300,000 authorized restricted stock units on September 8, 2009. Entitled employees are eligible to vest the first 50% of the total number of restricted stock awarded on September 8, 2012 and the second 50% on September 8, 2013 if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of September 8, 2009, which was US$4.40 per share, and assumes that the individual achieves the applicable corporate and individual objectives set forth in the award.

 

F-10
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

11. Stock-Based Compensation-Continued

 

On September 28, 2010, the Board of Directors approved the granting of the remaining 50,000 units out of the total 300,000 authorized restricted stock units under the 2010-2011 Plan. Entitled employees are eligible to vest the first 50% of the total number of restricted stock awarded on September 8, 2012 and the second 50% on September 8, 2013 if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of September 28, 2010, which was US$4.56 per share, and assumes that the individual achieves the applicable corporate and individual objectives set forth in the award.

 

On July 27, 2009, the Company’s subsidiary in Shenzhen entered into a 5-year consulting agreement with a consulting firm for consulting services related to developing strategies for rolling out the Company’s own branded consumer products in China. Pursuant to the agreement, the Company granted 500,000 restricted stock units from the Company’s 2006 Equity Incentive Plan to the consulting firm as compensation for the services. As of September 18, 2010, both parties decided to terminate the consulting arrangement and mutually waived the share-based compensation terms of the agreement.

 

On October 6, 2010, the Board of Directors approved the 2011-2013 Restricted Stock Unit Incentive Plan, the "2011-2013 Plan", a stock incentive compensation program for fiscal years 2011 to 2013. The 2011-2013 Plan allows the Company to offer a variety of restricted stock unit awards to directors, senior management and key employees of the Company’s wholly-owned subsidiary, Shenzhen PurCotton Technology Co., Ltd. The participant will be eligible to receive one share of the Company’s common stock for each restricted stock unit that vests upon the achievement of corporate and individual objectives and such participant’s continued employment as of the applicable vesting date.

 

Under the 2011-2013 Plan, the Company granted 300,000 units out of the total 500,000 authorized restricted stock units on October 6, 2010. On each of October 6, 2012, October 6, 2013 and October 6, 2014, a participant will be eligible to vest up to 1/3 of the total number of restricted stock units underlying an award if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of October 6, 2010, which was US$5.31 per share, and assumes that the individual achieves the applicable corporate and individual objectives set forth in the award.

 

On October 7, 2010, under the 2008-2009 Plan, the Company issued 179,507 shares of the Company’s common stock to those entitled employees, representing vesting of the first 50% of the total number of shares of restricted stock awarded.

 

Pursuant to a one-year consulting agreement signed between the Company and an investor relations consultant firm, 10,000 restricted stock units were granted to the consultant firm on the agreement date, which was May 1, 2010. After evaluating and assessing the accomplishments were achieved by the consultant firm, 10,000 restricted stock units were vested on May 2, 2011. The estimated value of the restricted stock units is based on the market price of the common stock as quoted on the NASDAQ.com as of May 2, 2011, which was US$4.99.

 

On October 7, 2011, the Company issued 231,625 shares of the Company’s common stock to those entitled employees, representing vesting of the second 50% of the total number of shares of restricted stock awarded.

 

On November 3, 2011, the Board of Directors approved the 2012-2013 Restricted Stock Unit and Options Incentive Plan, the "2012-2013 Plan", a stock incentive compensation program for fiscal years 2012 to 2013. This 2012-2013 Plan allows the Company to offer a variety of restricted stock units and/or options awards to directors, senior management and key employees, where a participant will be eligible to receive one share of the Company’s common stock for each restricted stock unit that vests upon the achievement of corporate and individual objectives and such participant’s continued employment as of the applicable vesting date.

 

Under the 2012-2013 Plan, the Company granted 530,000 restricted stock units on November 3, 2011. Entitled employees are eligible to vest the first 50% of the total number of shares of restricted stock awarded on November 3, 2014 and the second 50% on November 3, 2015 if the target of corporate net income attributable to Winner Medical Group Inc., annual Company sales objectives, and the participant’s individual performance objectives are fulfilled. The estimated value of award as of grant date is based on the market price of the common stock as quoted on the NASDAQ Global Market as of November 3, 2011, which was US$3.03 per share, and assumes that the individual achieves the applicable corporate and individual objectives set forth in the award.

 

F-11
 

  

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

11. Stock-Based Compensation-Continued

 

Under the 2012-2013 Plan, the Company granted 1,350,000 and 350,000 options to purchase one share of the Company’s common stock at US$3.08 and US$3.38, respectively, on November 3, 2011. On each of November 3, 2012, November 3, 2013, November 3, 2014 and November 3, 2015, entitled employees are eligible to vest up to 1/4 of the total number of option awards. The percentage of such vesting is predetermined for each individual and tied to satisfaction of the target corporate net income and annual sales objectives, as well as attainment of each participant’s personal performance targets. Each option award that is vested will expire two years after its vesting date. The Company utilizes the lattice-binomial option-pricing model (“binomial model”) to estimate the fair value of new employee stock option grants. The Company’s determination of fair value of stock option awards on the date of grant using the binomial model is affected by the Company’s stock price as well as assumptions regarding a number of variables. These variables include, but are not limited to the Company’s expected stock price volatility over the term of the awards, interest rates, option forfeitures and employee stock option exercise behaviors. The estimated weighted average fair value of awards was US$1.07 per option.

 

A summary of stock option activity is as follows:

 

           Weighted 
       Weighted   Average 
   Number of stock   Average   Remaining 
   options   Exercise Price   Contractual Life 
        US$   Years 
Balance at September 30, 2010 and 2011   0    0    0 
Options granted   1,700,000    3.14    4.00 
Outstanding at June 30, 2012   1,700,000    3.14    4.00 
Exercisable at June 30, 2012   0    0      

 

There was no option cancelled or exercised during the three and nine months ended June 30, 2012. As at June 30, 2012, the aggregated intrinsic value of options outstanding was US$1,374,000.

 

The weighted average estimated fair value of stock options granted during the nine months ended June 30, 2012 was determined using the binomial model with the following weighted average assumptions:

 

Term structure of risk-free interest rate   0.42%~1.25% 
Expected life   4.5 years 
Term structure of volatility   44.70%~46.70% 
Dividend yield   0 
Weighted average estimated fair value per option   US$1.07 

 

The risk-free interest rate assumption for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Expected volatility is based on historical volatility and implied volatility of the Company’s stock. The Company uses historical data to estimate option exercises and employee termination within the valuation model. The dividend yield assumption is based on the Company’s history and expectation of dividend payouts. The expected life of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is a derived output of the binomial model. The binomial model estimates employees’ exercise behavior based on the option’s remaining vested life and the extent to which the option is in-the-money. The binomial model estimates the probability of exercise as a function of these two variables based on the entire history of exercises and cancellations of all past option grants made by the Company.

 

The Company recorded stock-based compensation expenses included in selling, general and administrative expenses of US$384,569 and US$118,465 for the three months ended June 30, 2012 and 2011, respectively and US$1,129,392 and US$644,726 for the nine months ended June 30, 2012 and 2011, respectively.

 

Management considered that the fair value of outstanding restricted share units approximates the market value of the Company’s common stock of US$3.95 per share as at June 30, 2012.

 

As of June 30, 2012, a cumulative total of 1,051,306 non-vested restricted stock units have been cancelled and a cumulative total of 411,132 restricted stock units were vested. The total fair value of restricted stock units vested during the nine months ended June 30, 2012 and 2011, was US$697,191 and US$536,726, respectively.

 

F-12
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

11.  Stock-Based Compensation-Continued

 

A summary of the restricted stock units activity is as follows:

   2008-09 Plan
Number of
units
   2010-11 Plan
Number of
units
   2011-13 Plan
Number of units
   2012-13 Plan
Number of
units
   Total
Number of units
   Weighted
average
grant
date fair
value
US$
 
Nonvested units outstanding At September 30, 2010   478,750    287,250    0    0    766,000    3.53 
Granted   0    0    300,000    0    300,000    5.31 
Cancelled   (67,618)   (49,688)   (172,000)   0    (289,306)   4.60 
Vested   (179,507)   0    0    0    (179,507)   2.99 
Nonvested units outstanding at September 30, 2011   231,625    237,562    128,000    0    597,187    4.07 
Granted   0    0    0    530,000    530,000    3.03 
Cancelled   0    0    (128,000)   0    (128,000)   5.31 
Vested   (231,625)   0    0    0    (231,625)   3.01 
Nonvested units outstanding at June 30, 2012   0    237,562    0    530,000    767,562    3.46 

 

As of June 30, 2012, the unrecognized stock-based compensation expense for the 2010-2011 Plan, 2011-2013 Plan and 2012-2013 Plan was US$130,655, US$Nil and US$2,375,759, respectively, which totals US$2,506,414 and is expected to be amortized over the weighted average period of 1.99 years.

 

12.  Commitments and Contingencies

 

Operating leases - The Company was obligated under operating leases requiring minimum rentals as follows:

   US$ 
Three months ending September 30, 2012   688,574 
Years ending September 30,     
2013   1,895,772 
2014   886,771 
2015   322,407 
2016 and after   0 
Total minimum lease payments   3,793,524 

 

Rental expenses under operating leases included in the consolidated statements of income and comprehensive income were US$909,272 and US$647,159 for the three months ended June 30, 2012 and 2011, respectively. Rental expenses under operating leases for nine months ended June 30, 2012 and 2011, included in the consolidated statement of income and comprehensive income were US$2,630,246 and US$1,664,982, respectively.

 

Purchase obligations - The Company has signed agreements with suppliers and other parties to purchase plant and machinery and computer equipment with estimated non-cancelable obligations of US$5,997,376 and US$4,233,939 as of June 30, 2012 and September 30, 2011, respectively.

 

F-13
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

12.  Commitments and Contingencies - continued

 

Legal proceedings - Between April 9 and April 27, 2012, three purported shareholder class actions were filed against the Company, its board of directors and its chief executive officer, Jianquan Li, in District Court, Clark County, Nevada. The three purported shareholder class actions were later consolidated and, on August 9, 2012, the Company received a consolidated complaint (the "Consolidated Complaint"), wherein a purported class action claim was made against the Company, its board of directors and its chief executive officer, Jianquan Li (the “Class Action”). The Class Action arises from Mr. Li’s initial non-binding proposal on April 2, 2012 to acquire all outstanding shares of the Company’s common stock not owned or controlled by him or his wife in a “going private” transaction. The Class Action alleges that the Company’s board of directors have breached their fiduciary duties to the Company as a result of the proposed “going private” transaction, and that the Company has aided and abetted those alleged breaches. The Company has not yet responded to the Class Action, but believes the allegations therein are without merit. The Company intends to defend itself vigorously against the claims.

 

The Company has not yet been required to respond formally to this lawsuit. In addition, the Consolidated Complaint does not specify any amount of damages to be sought by plaintiffs. Because this matter is in a very early stage, the Company cannot determine whether or not an adverse outcome is probable, nor can it provide a reasonable estimate of any potential losses related to this matter. While the Company believes that it has meritorious defenses to the Class Action and intends to defend it vigorously, an adverse outcome in this matter could have a material adverse effect on the Company’s business, financial condition, results of operations or liquidity.

 

Other than the above, the Company is currently not aware of any such legal proceedings or claims that it believes it will have a material adverse affect on its business, financial condition or operating results. In addition, to the Company’s knowledge, no director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than five percent of the Company’s securities, or any associate of any such director, officer or security holder, is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

 

F-14
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

13.  Fair Value Measurement

 

FASB ASC 820, Fair Value Measurement, defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and requires certain disclosures about fair value measurement. FASB ASC topic 820 also establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

 

Level 1 - Quoted unadjusted prices for identical instruments in active markets.

 

Level 2 - Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in market that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.

 

Level 3 - Model-derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.

 

The financial instruments of the Company are cash and cash equivalents, restricted bank deposits, restricted broker margin account, accounts receivable, deposits and other receivable, other current assets, bank loans, accounts payable and other current liabilities are valued at fair values due to their short-term nature. These financial assets and liabilities are classified as either Level 1 or Level 2 in the fair value hierarchy as of June 30, 2012 and September 30, 2011. Fair value of the amounts due to or from affiliates cannot be readily determined because of the nature of the related party transactions.

 

Held-to-maturity investments - The Company’s held-to-maturity investments are carried at amortized cost. The fair value of held-to-maturity investments is approximated to the carrying value, based on the quoted prices for securities with similar characteristics and other observable inputs such as interest rates that are observable at commonly quoted intervals can be obtained directly from the commercial bank and such fair value measurement is considered as Level 2 in the fair value hierarchy.

 

The Company uses financial instruments to manage its exposures to movements in foreign exchange rates and commodity prices. The use of these financial instruments modifies the Company’s exposure to these risks with the goal of reducing the risk of cost to the Company. The Company does not use derivative financial instruments for speculative or trading purposes, nor does it hold or issue leveraged derivative financial instruments.

 

Foreign exchange derivatives - The Company’s operations are exposed to market risk primarily due to changes in currency exchange rates. In order to manage such risks so as to reduce volatility in earnings and cash flows, the Company enters into several foreign exchange forward contracts with a commercial bank to hedge for future trade receipts in U.S. dollars against RMB. No foreign exchange forward contracts were outstanding as of June 30, 2012. The Company’s foreign exchange forward contracts are classified as Level 2 in the fair value hierarchy under ASC 820 since the quoted prices of these foreign currency forward contracts can be obtained directly from the commercial bank.

 

F-15
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

13.  Fair Value Measurement -Continued

 

The following table summarizes the Company’s fair value of derivatives:

 

   Condensed Consolidated  June 30,   September 30, 
   Balance Sheet Presentation  2012   2011 
      US$   US$ 
Derivatives not designated as hedging instruments             
Fair value of foreign exchange forward  contracts  Prepaid expenses and other current assets   0    51,141 
              
Fair value of foreign exchange forward  contracts  Accrued and other liabilities   0    16,482 

 

The impact on earnings from foreign exchange derivatives activity, including changes in the fair value of derivatives for the three and nine months ended June 30, 2012 and 2011 are as follows:

 

      Three months ended 
   Presentation of gain or loss  June 30, 
   recognized on derivatives  2012   2011 
      US$   US$ 
Derivatives not designated as hedging instruments             
Foreign exchange forward contracts  Unrealized exchange gain   0    39,611 
   Unrealized exchange loss   0    (4,946)
              
   Other operating income, net   0    34,665 

 

      Nine months ended 
   Presentation of gain or loss  June 30, 
   recognized on derivatives  2012   2011 
      US$   US$ 
Derivatives not designated as hedging instruments             
Foreign exchange forward contracts  Unrealized exchange gain   0    79,560 
   Unrealized exchange loss   0    (8,489)
              
    Other operating income, net   0    71,071 

 

The realized gain on foreign exchange forward contracts included in other operating income, net was US$Nil in each of the three months ended June 30, 2012 and 2011, respectively. The realized loss on foreign exchange forward contracts included in other operating income was US$20,484 and realized gain was US$169,040 for the nine months ended June 30, 2012 and 2011, respectively.

 

Commodity derivatives - Cotton is the primary raw material used to manufacture many of the Company’s products and is purchased at market prices. Starting from October 2010, the Company uses commodity financial instruments to manage the risk of cotton purchase cost. Although the commodity financial instruments are economic hedges of specified risks, they are not designated or accounted for as hedging instruments. The commodity financial instruments are valued at fair value. The commodity derivatives require collateral, referred to as margin, in the form of cash. As of June 30, 2012, the Company’s restricted broker margin account was US$475,106, net of unrealized gain of US$Nil. As of June 30, 2012 and 2011, the fair value of commodity financial instruments decreased by US$Nil and US$73,738, respectively, which were recorded in other operating income. The total outstanding cotton futures contracts amounted to US$Nil as of June 30, 2012. The Company’s commodity financial instruments are classified as Level 1 in the fair value hierarchy under ASC Topic 820 since the quoted unadjusted prices of these commodity financial instruments are available in active markets.

 

The realized gain for the three months ended June 30, 2012 and 2011 on commodity financial instruments was US$92,791 and US$65,037, respectively. The realized gain for the nine months ended June 30, 2012 was US$167,467 and the realized loss for the nine months ended June 30, 2011 was US$1,694,632.

 

F-16
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

14.  Operating Risk

 

Concentrations of credit risk, major customers and suppliers - A substantial percentage of the Company’s sales are made to one customer, Sakai Shoten Co., Ltd, and are typically sold on an open account basis. The sales to Sakai Shoten Co., Ltd. accounted for 9.93% and 11.39% of the total net sales for the three months ended June 30, 2012 and 2011, respectively, and 9.09% and 12.07% of the total net sales for the nine months ended June 30, 2012 and 2011, respectively.

 

A substantial percentage of the Company’s accounts receivable are from three customers with balances that represented the following percentages of total accounts receivable at June 30, 2012 and September 30, 2011, respectively: Heng’an Group Ltd, 14.14% and 8.40%; Molnlycke Health Care AB, 9.98% and 15.14%; and Tyco Healthcare Co., Ltd, 9.95% and 10.05%. The Company has not experienced any significant difficulty in collecting its accounts receivable in the past and is not aware of any financial difficulties being experienced by its major customers.

 

Interest rate risk - The interest rates and terms of repayment of bank and other borrowings ranged from 6.36% to 7.87%. Other financial assets and liabilities do not have material interest rate risk.

 

Credit risk - In order to reduce the risk of inability to collect accounts receivable, the Company entered into an insurance policy with China Export & Credit Insurance Corporation effective on January 1, 2012. This insurance policy will expire on December 31, 2012 and is automatically renewable subject to a one month written notice given by either party. The maximum insurance coverage from China Export & Credit Insurance Corporation is US$2.5 million.

 

Foreign currency risk - The value of the Renminbi, the main currency used in the PRC, fluctuates and is affected by, among other things, changes in China's political and economic conditions. In addition, the Renminbi is not readily convertible into US dollars or other foreign currencies. All foreign exchange transactions continue to take place either through the Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China. The conversion of Renminbi into foreign currencies such as the US dollar has been generally based on rates set by the People's Bank of China, which are set daily based on the previous day's interbank foreign exchange market rates and current exchange rates on the world financial markets. On June 30, 2012 and September 30, 2011, the exchange rates of RMB against the US dollar were 6.3249 and 6.3549, respectively; the appreciation of RMB against the US dollar was 0.47%. On June 30, 2012 and September 30, 2011, the exchange rates of RMB against Euro were 7.8710 and 8.6328 respectively. This floating exchange rate, and any appreciation of the Renminbi that may result from such rate, could have a material adverse effect on the Company’s business and financial results.

 

F-17
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

15.  Geographical Information

 

The business of the Company is manufacturing and trading of medical dressings and medical disposable products. The Company's sales by geographic destination are analyzed as follows:

 

   Three months ended   Nine months ended 
   June 30,   June 30, 
   2012   2011   2012   2011 
   US$   US$   US$   US$ 
                 
Europe   16,410,903    16,071,074    43,073,676    35,684,291 
PRC   15,923,947    9,020,041    40,175,200    25,724,476 
North and South America   7,298,178    8,556,687    22,998,629    24,794,963 
Japan   5,426,130    6,201,565    16,779,429    16,834,536 
Others   3,132,813    1,687,098    7,800,449    5,422,519 
Total net sales   48,191,971    41,536,465    130,827,383    108,460,785 

 

Sales to countries which were in excess of 10% of total sales for the three and nine months ended June 30, 2012 and 2011, are as follows:

 

   Three months ended   Nine months ended 
   June 30,   June 30, 
   2012   2011   2012   2011 
   US$   US$   US$   US$ 
                 
PRC   15,923,947    9,020,041    40,175,200    25,724,476 
Japan   5,426,130    6,201,565    16,779,429    16,834,536 
United States of America   5,804,907    4,920,077    16,217,395    18,447,279 
Britain   2,848,530    4,369,665    7,841,422    9,573,037 

 

F-18
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

16.  Segment Information

 

The Company has two reportable segments: medical products (Medical Care, Wound Care, and Home Care) and PurCotton® products. The Company’s reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies.

 

Contributions of the major activities and profitability information of the Company’s reportable segments for the three and nine months ended June 30, 2012 and 2011, are as follows:

 

   Three months ended 
   June 30, 
   2012   2011 
   US$   US$ 
Net sales:          
Segment:          
Medical products   38,980,265    36,177,197 
PurCotton®  products   9,211,706    5,359,268 
Consolidated total   48,191,971    41,536,465 
           
Gross profits:          
Segment:          
Medical products   8,711,490    9,641,393 
PurCotton®  products   3,520,121    1,667,216 
Consolidated total   12,231,611    11,308,609 
           
Income before income taxes:          
Segment:          
Medical products   2,681,628    5,103,391 
PurCotton®  products   (366,361)   (1,102,819)
Consolidated total   2,315,267    4,000,572 
           
Net income attributable to Winner Medical Group Inc.:          
Segment:          
Medical products   2,379,861    4,315,020 
PurCotton®  products   (52,577)   (890,495)
Consolidated total   2,327,284    3,424,525 
           
Depreciation and amortization:          
Segment:          
Medical products   855,939    817,117 
PurCotton® products   687,716    579,499 
Consolidated total   1,543,655    1,396,616 

 

F-19
 

 

WINNER MEDICAL GROUP INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

16.  Segment Information-Continued

 

   Nine months ended 
   June 30, 
   2012   2011 
   US$   US$ 
Net sales:          
Segment:          
Medical products   107,187,537    94,548,622 
PurCotton®  products   23,639,846    13,912,163 
Consolidated total   130,827,383    108,460,785 
           
Gross profits:          
Segment:          
Medical products   25,391,656    25,554,717 
PurCotton®  products   7,844,363    4,587,111 
Consolidated total   33,236,019    30,141,828 
           
Income before income taxes:          
Segment:          
Medical products   9,681,607    12,247,619 
PurCotton®  products   (1,062,274)   (1,927,068)
Consolidated total   8,619,333    10,320,551 
           
Net income attributable to Winner Medical Group Inc.:          
Segment:          
Medical products   8,003,299    10,387,235 
PurCotton®  products   (1,287,878)   (1,398,530)
Consolidated total   6,715,421    8,988,705 
           
Depreciation and amortization:          
Segment:          
Medical products   2,583,065    2,465,766 
PurCotton® products   2,037,520    1,585,509 
Consolidated total   4,620,585    4,051,275 

 

   June 30,   September 30, 
   2012   2011 
   US$   US$ 
Total assets:          
Segment:          
Medical products   123,003,275    109,317,729 
PurCotton® products   50,674,985    45,578,410 
Segment total   173,678,260    154,896,139 
Reconciliation to consolidated totals:          
Elimination of other receivable from inter-segments   (10,056,375)   (4,977,452)
Consolidated total   163,621,885    149,918,687 

 

F-20
 

 

PART II

OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS.

 

Between April 9 and April 27, 2012, three purported shareholder class actions were filed against the Company, its board of directors and its chief executive officer, Jianquan Li, in District Court, Clark County, Nevada. The three purported shareholder class actions were later consolidated and, on August 9, 2012, the Company received a consolidated complaint (the "Consolidated Complaint"), wherein a purported class action claim was made against the Company, its board of directors and its chief executive officer, Jianquan Li (the “Class Action”). The Class Action arises from Mr. Li’s initial non-binding proposal on April 2, 2012 to acquire all outstanding shares of the Company’s common stock not owned or controlled by him or his wife in a “going private” transaction. The Class Action alleges that the Company’s board of directors have breached their fiduciary duties to the Company as a result of the proposed “going private” transaction, and that the Company has aided and abetted those alleged breaches. The Company has not yet responded to the Class Action, but believes the allegations therein are without merit. The Company intends to defend itself vigorously against the claims.

 

The Company has not yet been required to respond formally to this lawsuit. In addition, the Consolidated Complaint does not specify any amount of damages to be sought by plaintiffs. Because this matter is in a very early stage, the Company cannot determine whether or not an adverse outcome is probable, nor can it provide a reasonable estimate of any potential losses related to this matter. While the Company believes that it has meritorious defenses to the Class Action and intends to defend it vigorously, an adverse outcome in this matter could have a material adverse effect on the Company’s business, financial condition, results of operations or liquidity.

 

Other than the above, the Company is currently not aware of any such legal proceedings or claims that it believes it will have a material adverse affect on its business, financial condition or operating results. In addition, to the Company’s knowledge, no director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than five percent of the Company’s securities, or any associate of any such director, officer or security holder, is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

  

ITEM 6.EXHIBITS.

 

The list of exhibits required to be filed as exhibits to this Report are listed under the “Exhibit Index,” which is incorporated herein by reference.

 

6
 

 

SIGNATURES

 

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DATED: August 14, 2012

 

WINNER MEDICAL GROUP INC.  
   
By: / s/ Jianquan Li  
Jianquan Li  
Chief Executive Officer and Chairman  
(Principal Executive Officer)  
   
By: /s/ Xiuyuan Fang  
Xiuyuan Fang  
Chief Financial Officer and Treasurer  
(Principal Financial Officer)  

 

7
 

 

EXHIBIT INDEX

 

31.1Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

31.2Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

32.1Certification of Principal Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 

32.2Certification of Principal Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 

The following materials from the Winner Medical Group Inc. Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2012 filed on August 14, 2012 formatted in Extensible Business Reporting Language (XBRL):

(i)Condensed Consolidated Balance Sheets (Unaudited),
(ii)Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited),
(iii)Condensed Consolidated Statements of Stockholders’ Equity (Unaudited),
(iv)Condensed Consolidated Statements of Cash Flows (Unaudited), and
(v)Notes to Condensed Consolidated Financial Statements (Unaudited)

 

*  filed herewith

 

+XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

8

 

XFRA:3LW Quarterly Report 10-Q/A Filling

XFRA:3LW Stock - Get Quarterly Report SEC Filing of XFRA:3LW stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XFRA:3LW Quarterly Report 10-Q/A Filing - 6/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XFRA:3LW Quarterly Report 10-Q Filing - 6/30/2012  |  Next: XFRA:3NZ Western Gas Partners, LP Insider Activity 3 Filing - 8/6/2012